• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Pavmed gains FDA breakthrough nod for esophageal pre-cancer test

Pavmed gains FDA breakthrough nod for esophageal pre-cancer test

February 27, 2020 By Nancy Crotti

PavmedPavmed updated logo (NSDQ:PAVM) recently announced that its Lucid Diagnostics subsidiary has received FDA breakthrough device designation for its EsoGuard esophageal DNA test.

The test uses esophageal samples collected using Lucid’s 510(k)-cleared EsoCheck cell collection device from certain patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease (GERD). EsoGuard and EsoCheck are designed to facilitate the diagnosis of Barrett’s esophagus with and without dysplasia — a progression of precursor conditions that culminate in highly lethal esophageal cancer (EAC)— as well as EAC itself, in patients with chronic heartburn.

Although the American College of Gastroenterology (ACG) practice guidelines recommend screening in millions of high-risk patients to detect and treat Barrett’s esophagus, fewer than 10% actually undergo screening using the traditional invasive approach, upper endoscopy, according to PAVmed. Most patients diagnosed with EAC are either unaware of their underlying Barrett’s esophagus or of their missed opportunity to undergo treatment following an earlier diagnosis, the company added.

As a result, more than 80% die within five years of diagnosis. PAVmed estimated a minimum $2 billion immediately addressable domestic market opportunity for EsoGuard at at least $2 billion, based on clinical testing guidelines.

EsoGuard sequences bisulfite-converted DNA to detect methylation at 31 sites on two genes (VIM and CCNA1). It has been shown in a 408-patient human study published in Science Translational Medicine to be highly accurate at detecting BE, with and without dysplasia, as well as EAC, with greater than 90% sensitivity and specificity.

EsoGuard, which is already commercially available as a laboratory-developed test, is the subject of two Lucid-sponsored international multi-center IVD clinical trials in support of an FDA PMA. The screening study will enroll GERD patients without a prior diagnosis of Barrett’s esophagus or EAC who satisfy clinical screening guidelines. The case control study will enroll patients previously diagnosed with Barrett’s esophagus or EAC. In both studies, EsoGuard will be compared to the gold standard of endoscopy with biopsies. Both studies will begin enrolling patients in the coming weeks at 60 sites in the U.S. and Europe.

“EsoGuard’s FDA breakthrough device designation represents a major milestone for PAVmed and Lucid,” said Dr. Lishan Aklog, PAVmed’s chairman and CEO and Lucid’s executive chairman. “This designation validates our belief that EsoGuard is a groundbreaking technology that has the potential to have as great an impact on esophageal cancer as widespread Pap screening has had in preventing deaths from cervical cancer. We look forward to working closely with the FDA to advance our EsoGuard in-vitro diagnostic (IVD) clinical development program at an expedited pace.”

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Oncology Tagged With: FDA, Pavmed

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy